Literature DB >> 8135859

Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.

W D Jarvis1, L F Povirk, A J Turner, R S Traylor, D A Gewirtz, G R Pettit, S Grant.   

Abstract

We have demonstrated previously that bryostatin 1, a macrocylic lactone with putative protein kinase C (PKC)-activating properties, synergistically augments the antileukemic actions of the deoxycytidine analog 1-[beta-D-arabinofuranosyl]cytosine (ara-C) in HL-60 human promyelocytic leukemia cells (Grant et al., Biochem Pharmacol 42: 853-867, 1991), and that this effect appears to be related to sensitization to ara-C-induced apoptosis (Grant et al., Cancer Res 52: 6270-6278, 1992). In the present studies, we have assessed the extent of this damage by quantitative spectrofluorophotometry of small molecular weight, double-stranded DNA fragments in order to provide: (a) a more complete characterization of the interaction between ara-C and bryostatin 1, and (b) a direct comparison of the relative effects of bryostatin 1 treatment with other pharmacological manipulations known to modulate protein kinase C activity. Exposure of cells to ara-C (10(-9) to 10(-4) M; 1-24 hr) induced time- and concentration-related increases in the extent of DNA fragmentation. Treatment with bryostatin 1 (10(-11) to 10(-7) M; 1-24 hr) alone failed to induce DNA damage, but promoted substantial time- and concentration-related increases in the extent of fragmentation induced by a subsequent 6-hr exposure to ara-C. Maximal potentiation of fragmentation (e.g. 2- to 3-fold greater than that obtained with ara-C alone) was observed following a 24-hr pretreatment with 10(-8) M or 10(-7) M bryostatin 1, and correlated closely with enhanced inhibition of HL-60 cell clonogenicity. The stage-1 tumor-promoter phorbol dibutyrate potentiated the effects of ara-C in a biphasic manner, maximally augmenting the response at 2.5 x 10(-8) M, but exerting no effect at 10(-7) M, whereas the stage-2 tumor-promoter mezerein failed to augment ara-C-related DNA fragmentation at low concentrations, and antagonized ara-C action at high concentrations. In contrast, ara-C-related DNA fragmentation was attenuated or abolished either by continual preexposure to synthetic diglyceride or by pretreatment with exogenous phospholipase C at all concentrations tested. Increased DNA fragmentation was not specifically related to recruitment of cells into S-phase or enhancement of ara-C-related cellular differentiation. Finally, concentrations of bryostatin 1 that maximally potentiated ara-C-related DNA fragmentation were associated with virtually complete down-regulation of total cellular PKC activity, whereas diglyceride and phospholipase C, which suppressed the response to ara-C, moderately increased total PKC activity.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8135859     DOI: 10.1016/0006-2952(94)90484-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.

Authors:  Sneha Ramakrishna; Steven L Highfill; Zachary Walsh; Sang M Nguyen; Haiyan Lei; Jack F Shern; Haiying Qin; Ira L Kraft; Maryalice Stetler-Stevenson; Constance M Yuan; Jennifer D Hwang; Yang Feng; Zhongyu Zhu; Dimiter Dimitrov; Nirali N Shah; Terry J Fry
Journal:  Clin Cancer Res       Date:  2019-05-20       Impact factor: 12.531

2.  Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases.

Authors:  X J Huang; P H Wiernik; R S Klein; R E Gallagher
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

Review 3.  Protein kinase C targeting in antineoplastic treatment strategies.

Authors:  W D Jarvis; S Grant
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4.  Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.

Authors:  Robert J Morgan; Lucille Leong; Warren Chow; David Gandara; Paul Frankel; Agustin Garcia; Heinz-Josef Lenz; James H Doroshow
Journal:  Invest New Drugs       Date:  2010-10-09       Impact factor: 3.850

5.  Bryostatin-1 causes radiosensitization of BMG-1 malignant glioma cells through differential activation of protein kinase-Cδ not evident in the non-malignant AA8 fibroblasts.

Authors:  Raghubendra Singh Dagur; Shashank Hambarde; Sudhir Chandna
Journal:  Mol Cell Biochem       Date:  2014-12-04       Impact factor: 3.396

Review 6.  Mechanism targeted discovery of antitumor marine natural products.

Authors:  Dale G Nagle; Yu-Dong Zhou; Flor D Mora; Kaleem A Mohammed; Yong-Pil Kim
Journal:  Curr Med Chem       Date:  2004-07       Impact factor: 4.530

7.  Low dose docosahexaenoic acid protects normal colonic epithelial cells from araC toxicity.

Authors:  Ming C Cha; Angela Lin; Kelly A Meckling
Journal:  BMC Pharmacol       Date:  2005-03-23

8.  Bryostatin-1, Fenretinide and 1α,25 (OH)(2)D(3) Induce Growth Inhibition, Apoptosis and Differentiation in T and B Cell-Derived Acute Lymphoblastic Leukemia Cell Lines (CCRF-CEM and Nalm-6).

Authors:  Ali M Ardekani; Shahrzad Soleymani Fard; Mahmood Jeddi-Tehrani; Ramin Ghahremanzade
Journal:  Avicenna J Med Biotechnol       Date:  2011-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.